DARATUMUMAB
Gastroesophageal Cancer (GC)
Incyte Corporationmonoclonal_antibodyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Gastroesophageal Cancer (GC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FAPi-46 Barbara Malene Fischer | Phase 2 | CCC |
NUMIDARGISTAT Incyte Corporation | Phase 1/2 | CCC |
bhb810 BigHat Biosciences, Inc. | Phase 1/2 | CC |
MAT2A-IN-9 IDEAYA Biosciences | Phase 1 | CC |
Ctx-10726 Compass Therapeutics | Phase 1 | CC |
ide892 IDEAYA Biosciences | Phase 1 | CC |
Same molecule, other indications
DARATUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →